Status: Recruiting
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as induction therapy. The clinical remission rate, MRD negative rate and treaty-related adverse reactions were evaluated.
Participants needed: 124
Trial details
Phase: Phase 2Age: 15-65Biological sex: AllType: InterventionalSponsor: Chen SuningUpdated: Apr 4, 2024Locations: 1
Eligibility criteria
Age 15-65 [+6]
Ph+ (BCR-ABL1 positive) ALL [+9]